Zhujiang hospital
Guangzhou, Guangdong, China
Location status: Recruiting
Location contact
Chuanzhi Duan
CONTACT
Xifeng Li, MD
SUB_INVESTIGATOR
Xin Feng, MD
SUB_INVESTIGATOR
Xin Zhang, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06446778
This study collected the clinical, laboratory, and imaging data from patients with intracranial aneurysms, who underwent Pipeline implantation. The purpose of this study is to observe the safety, effcacy, and haemodynamics after Pipeline embolization.
Interested in participating?
Request Info22 year–75 year
All sexes
Observational
Guangzhou, Guangdong, China
Location status: Recruiting
Chuanzhi Duan
CONTACT
Xifeng Li, MD
SUB_INVESTIGATOR
Xin Feng, MD
SUB_INVESTIGATOR
Xin Zhang, MD
PRINCIPAL_INVESTIGATOR
This study collected the clinical, laboratory, and imaging data from patients with intracranial aneurysms, who underwent Pipeline implantation. The purpose of this study is to observe the safety, effcacy, and haemodynamics after Pipeline embolization. The primary outcomes were aneurysmal occlusion status, incidence of in-stent stenosis, and functional prognosis. The secondary outcomes were hemodynamic changes before and after stent implantation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The patients undenwent Pipeline embolization device implantation with or without shield technique due to market availability, choice and preferences of the surgeon.
Time frame: 1 years
The occlusion rate of the aneurysm at 6 months;O'Kelly Marotta classification: complete occlusion (D, entirely non-filling), near-complete occlusion (C, only entry remnant), and incomplete occlusion (A and B, subtotal and total filling).
Time frame: 1 years
In-stent stenosis is defined as a growth process beyond the limits of stent mesh, which appears as a visible gap between the vessel lumen filled with contrast agent and stent struts.
Stenosis ratio (SR) = [1-(actual diameter of the most stenotic segment with digital subtraction/actual diameter of stent measured on without digital subtraction)]*100%
When there was no appreciable gap, cases were described as patency. Intimal hyperplasia was labeled when the SR was less than 25 %. ISS was defined as an SR of ≥ 25 %, and the stenosis grade was classified as mild (25 % to 49 %), severe (50 % to 99 %), or lumen occlusion (SR = 100 %)
Time frame: 1 months
perioperative complications;such as arterial perforation, iatrogenic arterial dissection, embolization in previously uninvolved vascular territory, arterial access site hematoma, and retroperitoneal hematoma. Arterial perforation will be defined at angiography by the operator and associated with subarachnoid hemorrhage. Iatrogenic arterial dissection will be defined at angiography by the operator. Arterial access site hematoma will be assessed as a complication of arterial access puncture and defined by clinical examination and anatomic imaging. Retroperitoneal hematoma will be assessed as a complication of groin puncture and defined by imaging (ultrasound or CT or MR angiography). The definition of embolization in previously uninvolved vascular territory is noted after recanalization of the primary occlusion site, any vessel occlusions distal from the primary occlusion site are considered emboli due to periprocedural thrombus fragmentation.
Contact information is provided by the study sponsor or research team.
Chuanzhi Duan, MD
CONTACT
Xin Feng, MD
CONTACT
Zhujiang Hospital
Other
Pipeline Embolization Device for Intracranial Aneurysm (PEDIA): a Prospective, Multicenter Cohort Focus on Safety, Efficacy, and Haemodynamics
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05164263
Diabetes Mellitus, Diabetes Mellitus, Type 2
Kabul, Afghanistan
View Trial DetailsNCT04861506
Cardiovascular Diseases, Efficacy, Self
Hangzhou, Zhejiang, China
View Trial DetailsNCT06987760
Efficacy, Self, Female Urogenital Diseases
Ningbo, Zhejiang, China
View Trial DetailsNCT05583006
Behavior, Drug Adherence
Taichung, Taiwan
View Trial Details